Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 2
1992 3
1993 2
1994 1
1995 11
1996 6
1997 6
1998 11
1999 11
2000 15
2001 9
2002 12
2003 10
2004 8
2005 7
2006 8
2007 10
2008 16
2009 13
2010 17
2011 18
2012 13
2013 17
2014 19
2015 27
2016 22
2017 22
2018 35
2019 30
2020 26
2021 33
2022 23
2023 20

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Results by year

Filters applied: . Clear all
Page 1
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Evans DG, Plotkin SR. Legius E, et al. Among authors: wolkenstein p. Genet Med. 2021 Aug;23(8):1506-1513. doi: 10.1038/s41436-021-01170-5. Epub 2021 May 19. Genet Med. 2021. PMID: 34012067 Free PMC article.
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Wolkenstein P, Evans DG. Plotkin SR, et al. Among authors: wolkenstein p. Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007. Epub 2022 Jun 9. Genet Med. 2022. PMID: 35674741 Free article.
Severe cutaneous adverse reactions to drugs.
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Duong TA, et al. Among authors: wolkenstein p. Lancet. 2017 Oct 28;390(10106):1996-2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2. Lancet. 2017. PMID: 28476287 Review.
[Foreword].
Lok C, Vabres P, Beylot-Barry M, Wolkenstein P. Lok C, et al. Among authors: wolkenstein p. Ann Dermatol Venereol. 2015 Jun;142 Suppl 2:S23. doi: 10.1016/j.annder.2015.02.010. Epub 2015 Apr 4. Ann Dermatol Venereol. 2015. PMID: 25846465 French. No abstract available.
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. Bastuji-Garin S, et al. Among authors: wolkenstein p. J Invest Dermatol. 2000 Aug;115(2):149-53. doi: 10.1046/j.1523-1747.2000.00061.x. J Invest Dermatol. 2000. PMID: 10951229 Free article.
[Disulone].
Begon E, Chosidow O, Wolkenstein P. Begon E, et al. Among authors: wolkenstein p. Ann Dermatol Venereol. 2004 Dec;131(12):1062-73. doi: 10.1016/s0151-9638(04)93842-2. Ann Dermatol Venereol. 2004. PMID: 15692440 Review. French.
MEK inhibitors in RASopathies.
Bergqvist C, Wolkenstein P. Bergqvist C, et al. Among authors: wolkenstein p. Curr Opin Oncol. 2021 Mar 1;33(2):110-119. doi: 10.1097/CCO.0000000000000711. Curr Opin Oncol. 2021. PMID: 33395032 Review.
418 results